• University of Pennsylvania Featured PhD Programmes
  • University of Cambridge Featured PhD Programmes
  • Aberdeen University Featured PhD Programmes
  • Staffordshire University Featured PhD Programmes
  • University of Tasmania Featured PhD Programmes
University of Tasmania Featured PhD Programmes
University of Liverpool Featured PhD Programmes
EPSRC Featured PhD Programmes
University of Bristol Featured PhD Programmes
University of Reading Featured PhD Programmes

PhD studentship in Northern Institute for Cancer Research: Understanding synthetic lethality of ATR inhibitors with DDR dysregulation common in ovarian cancer

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Prof Curtin
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

This project aims to explore the therapeutic potential of an ATR inhibitor, developed at Vertex Pharmaceuticals, in ovarian cancer through exploitation of defects in the DNA damage response (DDR). ATR is key to the DDR by signalling DNA damage to cell cycle checkpoints and repair. Certain defects in the DDR confer sensitivity to ATR inhibition. Many of these defects are common in ovarian cancer, the 5th most frequent cause of cancer death in women. The project will involve cytotoxicity studies in a panel of ovarian cancer cell lines, knockdown of DDR genes, mechanistic studies to determine why some DDR defects confer sensitivity to ATR inhibition and translational studies using primary cultures of ovarian cancer from patients. Training in relevant biochemical and molecular techniques, the scientific method and intellectual rigor will be given. Parts of the project will be undertaken at Vertex, the industrial sponsor’s laboratories.

You must have, or expect to achieve, at least a 2:1 Honours degree in biology, biochemistry, biomedicine, or a related area. A further qualification such as an MSc or MRes is advantageous.

This award is available to UK/EU applicants. Depending on how you meet the MRC’s eligibility criteria (http://www.mrc.ac.uk/skills-careers/studentships/studentship-guidance/student-eligibility-requirements/), you may be entitled to a full or a partial award.

If English is not your first language, you must have IELTS 7 with at least 6.5 in the written component, or equivalent.

How to apply.

You must apply through the University’s online postgraduate application system - http://www.ncl.ac.uk/postgraduate/apply/. To do this please ‘Create a new account’.

Only mandatory fields need to be completed. However, you will need to include the following information:

• insert the programme 8300F in the programme of study section
• select ‘PhD in the Faculty of Medical Sciences – Cancer Research’ as the programme of study
• insert the studentship code CR073 in the studentship/partnership reference field
• attach a covering letter and CV. The covering letter must state the title of the studentship, quote the studentship reference code CR073 and state how your interests and experience relate to the project
• attach degree transcripts and certificates and, if English is not your first language, a copy of your English language qualifications

Funding Notes

Sponsor: Medical Research Council (MRC) http://www.mrc.ac.uk/ - Industrial CASE with Vertex Pharmaceuticals (Europe) Ltd http://www.vrtx.com/

Value of award - 100% of UK/EU tuition fees paid and annual living expenses of approximately £14,057 (full award) plus £2,500 from the industrial sponsor. A partial award covers fees at the UK/EU rate only.

Also significant additional funding to cover research costs and local, national and international travel (conferences and exchanges).

Share this page:

Cookie Policy    X